Currently, out of the existing stock ratings of Cory Kasimov - 74 which are a Buy (76.29%), 20 which are a Hold (20.62%), 3 which are a Sell (3.09%)

Cory Kasimov

Work Performance Price Targets & Ratings Chart

Analyst Cory Kasimov works at JPMORGAN and is covering the Healthcare sector with 219 price targets and ratings displayed on 25 stocks.

Cory Kasimov's average stock forecast success ratio is 65.61% with an average time for price targets to be met of 327.36 days.

Most recent stock forecast was given on KRTX, Karuna Therapeutics at 05-Jun-2023.

Wall Street Analyst Cory Kasimov

Analyst best performing recommendations are on EDIT (EDITAS MEDICINE).
The best stock recommendation documented was for EDIT (EDITAS MEDICINE) at 2/29/2016. The price target of $32 was fulfilled within 3 days with a profit of $3.05 (10.54%) receiving and performance score of 35.12.

Average potential price target upside

of $101.86 (37.91%) on MRNA (MODERNA).
of $91.6 (24.51%) on REGN (REGENERON PHARMACEUTICALS).
of $62.54 (23.5%) on BIIB (BIOGEN).

ACAD ACADIA Pharmaceuticals ALKS Alkermes plc BLUE bluebird bio BMRN BioMarin Pharmaceutical BNTX BioNTech SE Sponsored ADR CLVS Clovis Oncology GILD Gilead Sciences INCY yte MRNA Moderna NVCR NovoCure PBYI Puma Biotechnology RARE Ultragenyx Pharmaceutical SANA VRTX Vertex Pharmaceuticals SAGE Sage Therapeutics AMGN Amgen CERE Cerevel Therapeutics Holdings EDIT Editas Medicine GBT Global Blood Therapeutics KRTX Karuna Therapeutics REGN Regeneron Pharmaceuticals BIIB Biogen CELG JNCE LEGN

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Jeffrey Hung (MORGAN STANLEY)